Dengue 2 Vaccine: Dose Response in Volunteers in Relation to Yellow Fever Immune Status

A live dengue 2 vaccine was tested in 38 volunteers in an evaluation of the safety, infectivity, and immunogenicity of doses of 101.8–105.5 plaque-forming units. Twenty yellow fever-immune and 18 yellow fever-nonimmune individuals received 0.5 ml of vaccine sc. Immunization was dose related in yello...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1983-12, Vol.148 (6), p.1055-1060
Main Authors: Scott, R. McN, Eckels, K. H., Bancroft, W. H., Summers, P. L., McCown, J. M., Anderson, J. H., Russell, P. K.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antibodies
Antibodies, Viral - analysis
Arboviroses
Biological and medical sciences
Complement Fixation Tests
Dengue
Dengue - prevention & control
Dengue fevers
dengue virus
Dengue Virus - immunology
Dengue Virus - physiology
Dosage
Dose-Response Relationship, Immunologic
Female
Hemagglutination Inhibition Tests
Human viral diseases
Humans
Infectious diseases
Male
Medical research
Medical sciences
Middle Aged
Miscellaneous
Neutralization Tests
Neutralizing antibodies
Tropical medicine
Tropical viral diseases
Vaccination
Vaccines
Vaccines, Attenuated - immunology
Viral cardiopathies
Viral diseases
Viral Vaccines - adverse effects
Viral Vaccines - immunology
Viremia
Viruses
Volunteerism
Yellow fever
yellow fever virus
Yellow fever virus - immunology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A live dengue 2 vaccine was tested in 38 volunteers in an evaluation of the safety, infectivity, and immunogenicity of doses of 101.8–105.5 plaque-forming units. Twenty yellow fever-immune and 18 yellow fever-nonimmune individuals received 0.5 ml of vaccine sc. Immunization was dose related in yellow fever-immune volunteers, with a 50% immunizing dose of 103.3 plaque-forming units. In the group not immune to yellow fever, some but not all recipients of each vaccine dilution were immunized, and no 50% immunizing dose could be estimated. Volunteers immune to yellow fever developed adequate titers of neutralizing antibody to dengue 2 virus and maintained them for at least three years; those not immune to yellow fever developed lower antibody titers that disappeared within six months in half of the cases. More than 40 isolates of dengue 2 virus from 12 volunteers retained the in vitro growth characteristics of the vaccine virus; this result affirmed the genetic stability of the virus. Common clinical signs in immunized individuals were leukopenia (55%), macular rash (15%), and fever (10%).
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/148.6.1055